Skip to Content

Hetlioz LQ (tasimelteon) Disease Interactions

There are 4 disease interactions with Hetlioz LQ (tasimelteon):


Anxiolytics/sedatives/hypnotics (Includes Hetlioz LQ) ↔ depression

Major Potential Hazard, Moderate plausibility. Applies to: Depression

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.


  1. "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.
  2. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical, Abbott Park, IL.
  3. "Product Information. Sonata (zaleplon)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
  4. "Product Information. Equanil (meprobamate)." Wallace Laboratories, Cranbury, NJ.
  5. "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca, Plattsburg, NY.
View all 5 references

Anxiolytics/sedatives/hypnotics (Includes Hetlioz LQ) ↔ severe renal impairment

Major Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.


Anxiolytics/sedatives/hypnotics (Includes Hetlioz LQ) ↔ glaucoma

Moderate Potential Hazard, Moderate plausibility. Applies to: Glaucoma/Intraocular Hypertension, Urinary Retention

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.


Anxiolytics/sedatives/hypnotics (Includes Hetlioz LQ) ↔ liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

Hetlioz LQ (tasimelteon) drug interactions

There are 351 drug interactions with Hetlioz LQ (tasimelteon)

Hetlioz LQ (tasimelteon) alcohol/food interactions

There is 1 alcohol/food interaction with Hetlioz LQ (tasimelteon)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.